Harsh Singh Rajput

Harsh Singh Rajput is a pharmacist currently working at ESIC and holds an MBA in Pharmaceutical Management from NIPER Hyderabad. He has a strong academic record with top ranks in national-level pharmacy exams, including AIR 61 in NIPER 2024 (MS/M.Pharm), AIR 27 in NIPER MBA, AIR 147 in GPAT 2024, AIR 907 in GPAT 2023, and AIR 6 in AIIMS CRE-2025 for Drug Store Keeper. At PharmacyFreak.com, he contributes expert content, exam strategies, and practical guidance for future pharmacists. Mail- harsh@pharmacyfreak.com

PCI B.Pharm Syllabus 2026: New Semester-Wise Subjects, Credits, Exam Pattern & Major Changes

July 16, 2026 Harsh Singh Rajput

New PCI B.Pharm syllabus 2026 covering subjects, credits and exam pattern

The Pharmacy Council of India (PCI) has notified a new Bachelor of Pharmacy (B.Pharm) syllabus for 2026, aligned with the National Education Policy (NEP) 2020. The new curriculum introduces Python programming, pharmaceutical data analytics, machine learning, multiple AI-focused courses, startup education, skill-based electives, two internships, research projects, industry exposure and a revised credit-based examination system. … Read more

Mechanism of Action of Orilissa

July 15, 2026 Harsh Singh Rajput

Introduction Orilissa is the brand name of elagolix, an oral nonpeptide gonadotropin-releasing hormone receptor antagonist used for the management of moderate to severe pain associated with endometriosis. Endometriosis is a chronic estrogen-dependent inflammatory disorder in which endometrial-like tissue grows outside the uterus, commonly on the ovaries, fallopian tubes, pelvic peritoneum, uterosacral ligaments, bowel, or bladder. … Read more

Mechanism of Action of Trametinib

July 15, 2026 Harsh Singh Rajput

Introduction Trametinib is an oral targeted anticancer drug marketed under the brand name Mekinist. Pharmacologically, trametinib belongs to the mitogen-activated extracellular signal-regulated kinase inhibitor class, commonly called MEK inhibitors. MEK1 and MEK2 are important kinases in the RAS-RAF-MEK-ERK signaling pathway. This pathway regulates cell growth, proliferation, survival, differentiation, and migration. In several cancers, mutations in … Read more

Mechanism of Action of Guselkumab

July 14, 2026 Harsh Singh Rajput

Introduction Guselkumab is a biologic immunomodulator used in inflammatory immune-mediated diseases. It is marketed under the brand name Tremfya. Pharmacologically, guselkumab is an interleukin-23 antagonist and a human IgG1 lambda monoclonal antibody. Interleukin-23, commonly called IL-23, is an important cytokine involved in chronic inflammation. It plays a major role in the activation and maintenance of … Read more

Mechanism of Action of Riociguat

July 14, 2026 Harsh Singh Rajput

Introduction Riociguat is an oral pulmonary vasodilator used in selected forms of pulmonary hypertension. It is marketed under the brand name Adempas. Pharmacologically, riociguat belongs to the soluble guanylate cyclase stimulator class, commonly abbreviated as sGC stimulators. Pulmonary hypertension is a condition in which pressure within the pulmonary arterial circulation becomes abnormally high. This increases … Read more

Mechanism of Action of Verzenio

July 13, 2026 Harsh Singh Rajput

Introduction Verzenio is the brand name of abemaciclib, an oral targeted anticancer drug used in selected patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Pharmacologically, Verzenio belongs to the cyclin-dependent kinase 4 and 6 inhibitor class, commonly called CDK4/6 inhibitors. CDK4 and CDK6 are key enzymes that regulate progression of cells … Read more

Mechanism of Action of Kesimpta

July 13, 2026 Harsh Singh Rajput

Introduction Kesimpta is the brand name of ofatumumab, a subcutaneous monoclonal antibody used for relapsing forms of multiple sclerosis. Pharmacologically, Kesimpta is a CD20-directed cytolytic antibody. It is used in adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis. Multiple sclerosis is an immune-mediated … Read more

Mechanism of Action of Latuda

July 12, 2026 Harsh Singh Rajput

Introduction Latuda is the brand name of lurasidone hydrochloride, an oral atypical antipsychotic drug. It is mainly used for schizophrenia and depressive episodes associated with bipolar I disorder. Pharmacologically, lurasidone is classified as a second-generation antipsychotic, also called an atypical antipsychotic. Lurasidone works by modulating dopamine and serotonin neurotransmission in the brain. The exact therapeutic … Read more

Mechanism of Action of Tafamidis

July 12, 2026 Harsh Singh Rajput

Introduction Tafamidis is an oral disease-modifying drug used for transthyretin amyloid cardiomyopathy, commonly abbreviated as ATTR-CM. It is marketed under the brand names Vyndaqel and Vyndamax. Pharmacologically, tafamidis is a transthyretin stabilizer. Transthyretin, or TTR, is a transport protein mainly produced by the liver. It normally circulates as a tetramer, meaning it is made of … Read more

Mechanism of Action of Ponatinib

July 12, 2026 Harsh Singh Rajput

Introduction Ponatinib is an oral targeted anticancer drug used in selected Philadelphia chromosome-positive leukemias. It is marketed under the brand name Iclusig. Pharmacologically, ponatinib belongs to the BCR-ABL tyrosine kinase inhibitor class and is often described as a third-generation BCR-ABL inhibitor. Philadelphia chromosome-positive chronic myeloid leukemia, or Ph+ CML, and Philadelphia chromosome-positive acute lymphoblastic leukemia, … Read more